Search results for " vaccine"

Article Novel Vaccine Technologies Meet the Need for Pandemic and Therapeutic Solutions
Following the 2009 outbreak of the H1N1 pandemic flu and the numerous delays in producing vaccines against the virus, the US Department of Health and Human Services (HHS) recognized the need to invest…

Article Can Vaccine Development Be Safely Accelerated?
Biopharma companies responding to the COVID-19 outbreak think accelerating the development of vaccines is safe. By Cynthia A. Challener  MONGKOLCHON - STOCK.ADOBE.COM …

Article Vaccine Development Faces Urgency and Challenges
By Jill Wechsler The Ebola outbreak in 2015 and the current stampede to develop a new vaccine to combat the Zika virus illustrate the increasingly important role of vaccines in advancing public he…

Article Lessons Learned Accelerate Vaccine Development
The biopharmaceutical industry is focused on accelerating the development of new vaccines for such diseases and enabling the rapid response to unforeseen appearances of new viral threats. The successe…

Article Vaccine Development and Production Challenges Manufacturers
Researchers are advancing new vaccines for Ebola and other devastating diseases, while manufacturers work with FDA to bring to market new products to combat dangerous infections and strategies to impr…

Article Modern Manufacturing Key to More Effective Vaccines
By Jill Wechsler A lethal influenza outbreak this past winter has spotlighted the importance of improving and accelerating vaccine discovery and production. Reports that this year…

Article Ensuring Viral Safety of Viral Vaccines and Vectors
Viral vaccines rely on antigenic properties of a virus or virus-like particle (VLP) to trigger an immune response against an incipient viral infection. Because of the risks associated with live and in…

Article Bioprocessing Advances in Vaccine Manufacture
The vaccine industry, particularly, in major Western markets, continues to be dominated by a few major, long-established players that primarily manufacture aging, long-marketed, non-recombinant (nonge…

Article Approaches for Flexible Manufacturing Facilities in Vaccine Production
For influenza vaccines, the wholesale price paid to manufacturers ranges from $5 to $9 per dose (2). Doses that reach the market early in the season command a higher than average price, and prices dec…

Article EMA Invites Comments on New Guidance for Vaccine Development
The guidance covers the non-clinical and clinical requirements for the development of new influenza vaccines and aims to facilitate the prompt assessment of new vaccines. It follows the publication of…

Next Page